HomeCompareFSK vs RMD

FSK vs RMD: Dividend Comparison 2026

FSK yields 18.89% · RMD yields 1.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSK wins by $46.9K in total portfolio value
10 years
FSK
FSK
● Live price
18.89%
Share price
$9.95
Annual div
$1.88
5Y div CAGR
2.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.7K
Annual income
$8,463.51
Full FSK calculator →
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →

Portfolio growth — FSK vs RMD

📍 FSK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSKRMD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSK + RMD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSK pays
RMD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSK
Annual income on $10K today (after 15% tax)
$1,606.03/yr
After 10yr DRIP, annual income (after tax)
$7,193.98/yr
RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
At 15% tax rate, FSK beats the other by $4,398.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSK + RMD for your $10,000?

FSK: 50%RMD: 50%
100% RMD50/50100% FSK
Portfolio after 10yr
$55.2K
Annual income
$5,875.87/yr
Blended yield
10.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RMD right now

FSK
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$15.00
+50.8% upside vs current
Range: $15.00 — $15.00
Altman Z
-0.0
Piotroski
3/9
RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSK buys
0
RMD buys
0
No recent congressional trades found for FSK or RMD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSKRMD
Forward yield18.89%1.06%
Annual dividend / share$1.88$2.33
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.3%35.9%
Portfolio after 10y$78.7K$31.7K
Annual income after 10y$8,463.51$3,288.25
Total dividends collected$46.6K$10.4K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldBuy
Analyst price target$15.00$295.88

Year-by-year: FSK vs RMD ($10,000, DRIP)

YearFSK PortfolioFSK Income/yrRMD PortfolioRMD Income/yrGap
1← crossover$12,633$1,932.90$10,844$143.91+$1.8KFSK
2$15,852$2,334.56$11,801$198.21+$4.1KFSK
3$19,762$2,800.73$12,901$273.96+$6.9KFSK
4$24,484$3,338.26$14,185$380.39+$10.3KFSK
5$30,152$3,954.17$15,709$531.20+$14.4KFSK
6$36,918$4,655.67$17,556$747.16+$19.4KFSK
7$44,952$5,450.05$19,845$1,060.53+$25.1KFSK
8$54,444$6,344.63$22,757$1,522.63+$31.7KFSK
9$65,601$7,346.71$26,567$2,217.64+$39.0KFSK
10$78,657$8,463.51$31,715$3,288.25+$46.9KFSK

FSK vs RMD: Complete Analysis 2026

FSKBDC

FS KKR Capital Corp. is a business development company specializing in investments in debt securities. It provides customized credit solutions to private middle market U.S. companies. It invest primarily in the senior secured debt and, to a lesser extent, the subordinated debt of private middle market U.S. companies. It seeks to purchase interests in loans through secondary market transactions or directly from the target companies as primary market investments. It also seeks to invest in first lien senior secured loans, second lien secured loans and, to a lesser extent, subordinated loans, or mezzanine loans. In connection with the debt investments, the firm also receives equity interests such as warrants or options as additional consideration. It also seek to purchase minority interests in the form of common or preferred equity in our target companies, either in conjunction with one of the debt investments or through a co-investment with a financial sponsor. Additionally, on an opportunistic basis, the fund may also invest in corporate bonds and similar debt securities. The fund does not seek to invest in start-up companies, turnaround situations, or companies with speculative business plans. It seeks to invest in small and middle-market companies based in United States. The fund seeks to invest in firms with annual revenue between $10 million to $2.5 billion. It focus on providing customized one-stop credit solutions to private upper middle market companies with annual EBITDA of $50 million to $100 million at the time of investment. It seeks to exit from securities by selling them in a privately negotiated over- the- counter market. For any investments that are not able to be sold within the secondary market, the firm seeks to exit such investments through repayment, an initial public offering of equity securities, merger, sale or recapitalization.

Full FSK Calculator →

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →
📬

Get this FSK vs RMD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSK vs SCHDFSK vs JEPIFSK vs OFSK vs KOFSK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.